Clearside Biomedical Inc (CLSD)
Official siteBIOTECHNOLOGY
Last updated: Nov 13, 2026 at 4:00 PM ET
Clearside Biomedical Inc (CLSD) Financials: Revenue, Profit and Cash Flow
Clearside Biomedical reported revenue of $1.66M for the fiscal year ended Dec 31, 2024, down 79.8% from the year before. That year, net income was -$34.35M with a net margin of -2064.4%, operating cash flow was -$24.70M and free cash flow was -$25.68M. The quarter ended Sep 30, 2025 had revenue of $201.00K and net income of -$5.97M.
Revenue and Margins
Over the 8 years to Dec 2024, revenue grew from $520.00K, a compound annual rate of 15.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $1.66M | -79.8% | 91.0% | -1735.7% | -2064.4% |
| Dec 2023 | $8.23M | +519.9% | 95.7% | -302.0% | -394.9% |
| Dec 2022 | $1.33M | -95.5% | 84.6% | -2281.6% | -2482.8% |
| Dec 2021 | $29.57M | +274.7% | 100.0% | -2.1% | 1.3% |
| Dec 2020 | $7.89M | +263.3% | 100.0% | -227.2% | -228.4% |
| Dec 2019 | $2.17M | +7143.3% | 100.0% | -1394.6% | -1406.3% |
| Dec 2018 | $30.00K | -91.3% | 100.0% | -276483.3% | -276060.0% |
| Dec 2017 | $345.00K | -33.7% | 100.0% | -16929.9% | -17094.2% |
| Dec 2016 | $520.00K | N/A | 100.0% | -4845.8% | -4977.3% |
| Dec 2015 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2024, the net loss widened from the year before. In the quarter ended Sep 2025, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.66M | $8.23M | $1.33M | $29.57M | $7.89M | $2.17M | $30.00K | $345.00K | $520.00K | $0 |
| Cost of revenue | $149.00K | $355.00K | $204.00K | $178.00K | $0 | N/A | $0 | $58.57M | $25.65M | $33.00K |
| Gross profit | $1.51M | $7.87M | $1.12M | $29.57M | $7.89M | $2.17M | $30.00K | $345.00K | $520.00K | -$33.00K |
| Research and development | $18.59M | $20.85M | $19.63M | $18.54M | $15.07M | $15.66M | $68.29M | $49.05M | $19.45M | $10.76M |
| Operating income | -$28.88M | -$24.84M | -$30.28M | -$627.00K | -$17.93M | -$30.30M | -$82.94M | -$58.41M | -$25.20M | -$17.32M |
| Net income | -$34.35M | -$32.48M | -$32.95M | $376.00K | -$18.03M | -$30.56M | -$82.82M | -$58.98M | -$25.88M | -$17.64M |
| EBITDA | -$24.35M | -$23.06M | -$29.46M | $554.00K | -$17.75M | -$30.09M | -$82.76M | -$58.23M | -$25.13M | -$17.26M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $201.00K | $492.00K | $2.33M | $306.00K | $1.04M | $90.00K | $230.00K | $6.34M | $859.00K | $1.02M | $4.00K | $330.00K |
| Gross profit | $201.00K | $408.00K | $2.08M | $157.00K | $1.04M | $90.00K | $202.00K | $6.33M | $717.00K | $805.00K | $4.00K | $126.00K |
| Operating income | -$7.04M | -$3.57M | -$5.21M | -$7.15M | -$5.93M | -$7.59M | -$8.21M | -$2.92M | -$7.05M | -$7.27M | -$7.61M | -$8.07M |
| Net income | -$5.97M | -$4.50M | -$8.22M | -$7.31M | -$7.69M | -$7.59M | -$11.76M | -$4.83M | -$9.27M | -$9.11M | -$9.28M | -$8.59M |
Balance Sheet
As of Dec 2024, cash and equivalents of $20.02M were 79.7% of total assets of $25.13M, against total liabilities of $63.98M.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $25.13M | $34.02M | $51.30M | $42.90M | $19.32M | $26.78M | $44.12M | $40.49M | $84.81M | $21.05M |
| Current assets | $21.27M | $30.12M | $49.40M | $42.14M | $18.12M | $25.22M | $42.94M | $37.64M | $83.63M | $20.48M |
| Cash and equivalents | $20.02M | $28.92M | $48.26M | $30.44M | $17.29M | $22.59M | $8.04M | $9.22M | $34.82M | $20.28M |
| Total liabilities | $63.98M | $49.93M | $40.70M | $4.93M | $10.56M | $15.62M | $20.50M | $19.08M | $13.15M | $57.71M |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | $3.82M | $9.42M | $4.81M | $7.59M | $4.24M |
| Shareholder equity | -$38.85M | -$15.91M | $10.61M | $37.98M | $8.76M | $11.16M | $23.62M | $21.41M | $71.66M | -$36.66M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $11.64M | $15.33M | $19.67M | $25.13M | $29.16M | $33.93M | $40.14M | $34.02M | $34.42M | $39.19M | $44.70M | $51.30M |
| Total liabilities | $65.59M | $64.07M | $65.58M | $63.98M | $63.95M | $62.22M | $61.95M | $49.93M | $47.27M | $44.16M | $41.99M | $40.70M |
| Cash and equivalents | $6.80M | $9.38M | $13.63M | $20.02M | $13.89M | $18.24M | $35.35M | $28.92M | $28.80M | $35.01M | $41.42M | $48.26M |
| Shareholder equity | -$53.95M | -$48.73M | -$45.91M | -$38.85M | -$34.79M | -$28.29M | -$21.81M | -$15.91M | -$12.85M | -$4.97M | $2.70M | $10.61M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2024.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$24.70M | -$18.14M | -$13.37M | -$10.73M | -$13.12M | -$27.07M | -$79.20M | -$51.08M | -$22.71M | -$13.90M |
| Capital expenditures | $977.00K | $1.78M | $246.00K | $246.00K | $55.00K | $25.00K | $88.00K | $306.00K | $3.00K | $32.00K |
| Free cash flow | -$25.68M | -$19.91M | -$13.61M | -$10.98M | -$13.18M | -$27.09M | -$79.29M | -$51.39M | -$22.71M | -$13.93M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $308.00K | N/A |
| Investing cash flow | -$638.00K | -$1.78M | -$246.00K | -$246.00K | -$55.00K | $32.92M | -$3.76M | $20.12M | -$49.14M | -$28.00K |
| Financing cash flow | $16.44M | $414.00K | $31.33M | $23.78M | $7.87M | $8.70M | $81.78M | $5.36M | $86.39M | $25.94M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.48M | -$4.73M | -$5.83M | -$5.25M | -$5.91M | -$5.68M | -$7.85M | $495.00K | -$6.08M | -$5.34M | -$7.22M | -$5.61M |
| Capital expenditures | $9.00K | $0 | $9.00K | $444.00K | $53.00K | $423.00K | $57.00K | $120.00K | $445.00K | $1.10M | $115.00K | $91.00K |
| Free cash flow | -$5.49M | -$4.73M | -$5.84M | -$5.70M | -$5.97M | -$6.10M | -$7.91M | $375.00K | -$6.52M | -$6.44M | -$7.33M | -$5.70M |
Frequently Asked Questions About CLSD
What is Clearside Biomedical's annual revenue?
Clearside Biomedical reported revenue of $1.66M for the fiscal year ended Dec 31, 2024.
How fast is Clearside Biomedical's revenue growing?
Revenue was down 79.8% for the fiscal year ended Dec 31, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was -61.7%.
Is Clearside Biomedical profitable?
No. Clearside Biomedical reported net income of -$34.35M for the fiscal year ended Dec 31, 2024, with a net margin of -2064.4%.
How much free cash flow does CLSD generate?
For the fiscal year ended Dec 31, 2024, operating cash flow of -$24.70M minus capital expenditures of $977.00K produced free cash flow of -$25.68M.
How much debt does Clearside Biomedical have?
The balance sheet dated Dec 31, 2024 reported cash and equivalents of $20.02M.
CLSD pages: Overview, Financials